Roche wins FDA approval for Enspryng in thyroid eye disease

Roche has secured FDA approval for Enspryng (satralizumab) in adults with thyroid eye disease (TED), making it the first and only subcutaneous treatment for the condition that patients or caregivers can self-administer at home. The approval, granted following priority review, marks the second indication for the anti-IL-6 receptor monoclonal antibody, which has been approved for neuromyelitis optica spectrum disorder (NMOSD) since 2020.

TED, also known as Graves' ophthalmopathy, is a rare autoimmune condition affecting roughly 155 people per 100,000 in the United States. The disease causes inflammation around the eye socket, leading to proptosis (bulging of the eyes), diplopia (double vision), eyelid retraction, and in severe cases, sight-threatening complications. Despite existing approved therapies, the condition has historically posed a logistical challenge for patients, with available treatments requiring intravenous infusion in a clinical setting.

Trial data and mechanism

The approval draws on results from the Phase III SatraGO programme, comprising two identically designed, randomised, placebo-controlled studies across 258 patients in 19 countries. SatraGO-1 did not meet its pre-specified primary efficacy endpoint at week 24. SatraGO-2, however, achieved a statistically significant proptosis response rate of 52.9% in the Enspryng arm versus 23.4% for placebo in the active TED population, with diplopia reduction rates of 60.7% versus 25.8% respectively. Consistent findings were observed in the overall population, which included both active and chronic TED patients. No new safety signals were identified; the profile was consistent with Enspryng's established record in NMOSD across more than 16,000 patients.

Enspryng, originally developed by Chugai, a Roche Group member, is a humanised monoclonal antibody that binds both soluble and membrane-bound IL-6 receptors. It incorporates Chugai's proprietary antibody recycling technology, which enables pH-dependent binding and repeated target engagement, extending the antibody's circulation time and sustaining IL-6 pathway inhibition. During the maintenance phase, the drug is administered subcutaneously every four weeks.

César Briceño, clinical trial investigator and associate professor of ophthalmology at the Scheie Eye Institute, University of Pennsylvania, said the availability of a subcutaneous option "could provide greater flexibility for both patients and physicians while reducing the logistical burden associated with infusion-based therapies."

Market context and pipeline outlook

The TED treatment landscape has been reshaped in recent years by the approval of teprotumumab (Tepezza, Amgen/Horizon), an IGF-1R inhibitor administered intravenously, which became the first FDA-approved therapy for TED in 2020. Enspryng's subcutaneous, at-home dosing schedule offers a differentiated administration profile, though head-to-head comparative data with existing agents have not been presented. How payers and prescribers weigh convenience against comparative efficacy will be a key commercial variable in the near term.

Beyond TED, Roche is advancing Enspryng across a broader neurological autoimmune franchise. The FDA accepted a supplemental biologics licence application for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in September 2026, with an approval decision expected in January 2027. Additional studies are ongoing in autoimmune encephalitis subtypes, including anti-NMDA receptor and LGI1 variants, where Enspryng holds orphan drug designation. If MOGAD clearance follows, Enspryng would become a rare multi-indication antibody in the autoimmune neurology space, a positioning that could underpin significant label expansion and pricing leverage for Roche over the medium term.